Melanoma-associated retinopathy versus abnormal retinal function due to interferon-α/isotretinoin therapy in cutaneous malignant melanoma

Ophthalmologica

Volumn 214, Issue 4, 2000, Pages 271-276

  Feigl, Beatrix ^a   Faschinger, Christoph ^b   Soyer, Peter ^b  

^a Universitats Augenklinik   (Austria)

^b NONE

Author keywords

Interferon associated retinopathy; Isotretinoin associated retinopathy; Melanoma associated retinopathy

Indexed keywords

ALPHA INTERFERON; ISOTRETINOIN;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRY EYE; FEMALE; HUMAN; MALE; MELANOMA; MULTICENTER STUDY; NIGHT BLINDNESS; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; RETINOPATHY; TREATMENT OUTCOME;

EID: 0034045080     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000027503     Document Type: Article

References (20)

1. Berson EL, Lessel S: Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol 1988;106:307-311.
2. Cunninham WJ, Ehmann CW: Clinical aspects of the retinoids. Semin Dermatol 1983;2:145-160.
3. International Standardization Committee: Standard for clinical electroretinography. Arch Ophthalmol 1989;107:816-819.
4. Arden GB, Barrada A: Analysis of electro-oculograms of a series of normal subjects. Role of the lens in the development of the standing potential. Br J Ophthalmol 1962;46:301-303.
5. Kellner U, Bornfeld N, Foerster MH: Servere course of cutaneous melanoma-associated paraneoplastic retinopathy. Br J Ophthalmol 1995;79:746-752.
6. Kim RY, Retsas S, Fitzke FW, Arden GB, Bird AC: Cutaneous melanoma-associated retinopathy. Ophthalmology 1994;101:1837-1843.
7. Singh AD, Milam AH, Shields C, Potter P, Shields J: Melanoma-associated retinopathy. Am J Ophthalmol 1995;119:369-370.
8. Alexander KR, Fishman GA, Peachey NS, Marches AL, Tso OM: 'On' response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci 1992;33:477-483.
9. Matsui Y, Mehta MC, Katsumi O, Brodie S, Hirose T: Electrophysiological findings in paraneoplastic retinopathy. Graefes Arch Clin Exp Ophthalmol 1992;230:324-328.
10. Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR: Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 1996;34:91-100.
11. Weinstein JM, Kelman SE, Bresnick GH, Kornguth SE: Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology 1993;101:1236-1243.
12. Klopfer M, Schmidt Th, Leipert KP, Ugi J, Boeck K, Hofmann S: Melanom-assoziierte Retinopathie (MAR) mit Nachtblindheit. Ophthalmologe 1997;94:563-576.
13. Thirkill CE, Roth AM, Keltner JL: Cancer-associated retinopathy. Arch Ophthalmol 1987;105:372-375.
14. Fraunfelder FT, LaBraico JM, Meyer MS: Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthalmol 1985;100:534-537.
15. Heuberger A, Büchi ER: Irreversible Katarakt als mögliche Nebenwirkung von Isotretionin. Klin Monatsbl Augenheilkd 1994;204:465-467.
16. Kaiser-Kupfer MI, Peck GL, Caruso RC, Jaffe MJ, DiGiovanna JJ, Gross EG: Abnormal retinal function associated with fenretinide, a synthetic retinoid. Arch Ophthalmol 1986;104: 69-70.
17. Brown RD, Grattan CEH: Visual toxicity of synthetic retinoids. Br J Ophthalmol 1989;73: 286-288.
18. Weleber RG, Denman ST, Hanifin JM, Cunningham J: Abnormal retinal function associated with isotretionin therapy for acne. Arch Ophthalmol 1986;104:831-837.
19. Hayasaka S, Nagaki Y, Matsumoto M, Sato S: Interferon-associated retinopathy. Br J Ophthalmol 1998;82:323-325.
20. Guyer DR, Tiedemann J, Yannuzzi LA, Slater JS, Parke D, Kelley J, Tang R, Marmor M, Abrams G, Miller J, Gragoudas ES: Interferon-associated retinopathy. Arch Ophthalmol 1993;111:350-356.